Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avastin and Tarceva in unresectable hepatocellular carcinoma
NCT00242502Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Oct 2005
- Primary completion
- Oct 2011
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in hepatocellular carcinoma (HCC), sponsored by University of Texas MD Anderson Cancer Center. Started Oct 2005; status: completed.
02
Drugs
bevacizumaberlotinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00242502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00242502.